stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Revenue growth
ACADIA Pharmaceuticals Inc.'s revenue growth over the twelve months to 30 September 2026 was 14.8%, up 3.0 percentage points from fiscal 2025 (11.9%). Over the past ten years it has ranged from −49.2% (fiscal 2015) to 28,311.5% (fiscal 2016); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 11.9% | (19.98) |
| FY2024 | 31.9% | (8.60) |
| FY2023 | 40.5% | 33.62 |
| FY2022 | 6.83% | (2.77) |
| FY2021 | 9.60% | (20.68) |
| FY2020 | 30.3% | (21.22) |
| FY2019 | 51.5% | (27.69) |
| FY2018 | 79.2% | (541.49) |
| FY2017 | 620.7% | (27,690.80) |
| FY2016 | 28,311.5% | 28,360.65 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 22.9% | 6.45 |
| Jun 2026 | 16.4% | 6.68 |
| Mar 2026 | 9.72% | 0.33 |
| Dec 2025 | 9.39% | (1.88) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| IOVA Iovance Biotherapeutics, Inc. compare | 51.3% |
| TNGX Tango Therapeutics, Inc. compare | 48.3% |
| ACAD ACADIA Pharmaceuticals Inc. | 14.8% |
| XENE Xenon Pharmaceuticals Inc. compare | −8.15% |
| RLAY Relay Therapeutics, Inc. compare | −74.3% |
| VKTX Viking Therapeutics, Inc. compare | — |
| PBLS Parabilis Medicines, Inc. compare | — |
| IRON Disc Medicine, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement